SCHEMBL4664340

SCHEMBL4664340

Cc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc5c(ccn5CCN5CCN(C)CC5)c4)ncn3)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.35
BPTF Q12830 5/20 0.34
HTR7 P34969 2/20 0.34
EGFR P00533 2/20 0.33
ABL1 P00519 3/20 0.32
BCR P11274 3/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
GLA P06280 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666150 0.96 BPTF (0.35) BACE1BPTFEGFRABL1BCR
SCHEMBL4667474 0.95 BACE1 (0.35) BACE1BPTFEGFRABL1BCR
SCHEMBL4666098 0.91 BPTF (0.35) BACE1BPTFABL1BCRMEN1
SCHEMBL4665685 0.91 HTR7 (0.35) BACE1BPTFHTR7EGFRABL1
SCHEMBL4666209 0.90 ABL1 (0.38) BPTFEGFRABL1BCRTP53
SCHEMBL4665810 0.89 ABL1 (0.39) EGFRABL1BCRTP53TNNI3K
SCHEMBL4666171 0.88 ABL1 (0.36) BACE1BPTFHTR7EGFRABL1
SCHEMBL4665713 0.88 ABL1 (0.37) BACE1BPTFHTR7EGFRABL1
SCHEMBL4667458 0.88 HTR6 (0.41) BACE1BPTFEGFRABL1BCR
SCHEMBL4667488 0.87 EGFR (0.37) BPTFHTR7EGFRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 BACE1 4299/4885BPTF 2862/4885HTR7 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.